ARCHIVES

As patients worry about COX-2 inhibitors, scientists and FDA review toxicity data.

This article is from The Cancer Letter archive.

Vol. 30 No. 40 | October 22, 2004

Download PDF Visit The Full Archive

Related Articles

Tivozanib Trumps Sorafenib In 1st-Line Renal Cancer Study

May 25, 2012

Cancer Care Cost To Jump by 27 Percent In a Decade, Reaching $158 Billion in 2020

January 28, 2011

Core Grants Limit Formula Must Wait On Profiles

January 27, 1978

New Immunotherapy Increased Survival Of Neuroblastoma In Phase III Trial

September 24, 2010

President Drops Revision Plan; NCI To Receive $937.1 Million Voted By Congress For FY 1979

January 12, 1979

Supreme Court Lets Stand Lower Court Ruling On AZT Patents

January 19, 1996